We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

37 hedge funds and large institutions have $5.11M invested in Carisma Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.18% less ownership

Funds ownership: 14.7% → 12.53% (-2.2%)

30% less funds holding

Funds holding: 53 → 37 (-16)

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

45% less capital invested

Capital invested by funds: $9.28M → $5.11M (-$4.17M)

89% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 18

Holders
37
Holders Change
-16
Holders Change %
-30.19%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
8
Reduced
13
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$595K
2
Renaissance Technologies
Renaissance Technologies
New York
+$73K
3
Two Sigma Investments
Two Sigma Investments
New York
+$37K
4
WC
Wexford Capital
Florida
+$16.2K
5
Federated Hermes
Federated Hermes
Pennsylvania
+$1.8K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$354K
2
BlackRock
BlackRock
New York
-$327K
3
TGA
TPG GP A
Texas
-$304K
4
Jane Street
Jane Street
New York
-$243K
5
Northern Trust
Northern Trust
Illinois
-$161K
Name Holding Trade Value Shares
Change 		Change in
Stake
BTC
26
Bank & Trust Company
Illinois
$515 – – –
CPA
27
Capital Performance Advisors
California
$491 +$542 +500 New
PBK
28
Peoples Bank (Kansas)
Kansas
$245 – – –
UBS Group
29
UBS Group
Switzerland
$214 -$6 -6 -3%
IA
30
IFP Advisors
Florida
$203 – – –
OP
31
ORG Partners
Indiana
$196 – – –
National Bank of Canada
32
National Bank of Canada
Quebec, Canada
$162 +$125 +115 +230%
Nisa Investment Advisors
33
Nisa Investment Advisors
Missouri
$158 +$153 +141 +705%
Osaic Holdings
34
Osaic Holdings
Arizona
$139 – – –
HI
35
Harbour Investments
Wisconsin
$36 – – –
Citigroup
36
Citigroup
New York
$10 -$3.79K -3,502 -100%
MWA
37
MFA Wealth Advisors
Pennsylvania
$8 – – –
Goldman Sachs
38
Goldman Sachs
New York
– -$354K -232,793 Closed
Jane Street
39
Jane Street
New York
– -$243K -159,879 Closed
YIH
40
Y-Intercept (HK)
Hong Kong
– -$115K -75,501 Closed
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
– -$111K -73,323 Closed
CC
42
Centiva Capital
New York
– -$82.8K -54,500 Closed
PP
43
Paloma Partners
Connecticut
– -$48K -31,578 Closed
PAS
44
Point72 Asia (Singapore)
Singapore
– -$39.5K -26,006 Closed
Mirae Asset Global ETFs Holdings
45
Mirae Asset Global ETFs Holdings
Hong Kong
– -$19.8K -13,016 Closed
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
– -$12.7K -8,387 Closed
SSG
47
Summit Securities Group
New York
– -$8K -5,210 Closed
PD
48
Point72 (DIFC)
United Arab Emirates
– -$3.04K -1,996 Closed
Macquarie Group
49
Macquarie Group
Australia
– -$2.09K -1,373 Closed
Russell Investments Group
50
Russell Investments Group
United Kingdom
– -$980 -645 Closed
1
2
3

CARM Hedge Fund Activity: Q3 2024 in Review

37 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2024, worth a combined $5.11M — down 45% from $9.28M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CARM and 2 opened new positions — a net loss of 16 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was Barclays, adding an estimated $595K. The largest seller was Goldman Sachs, exiting entirely with an estimated $354K sold.

  • 37 institutional investors held Carisma Therapeutics (CARM) as of Q3 2024, down from 53 in Q2 2024.
  • Funds reported $5.11M of Carisma Therapeutics stock for Q3 2024, down 45% quarter-over-quarter.
  • 2 funds opened new Carisma Therapeutics positions in Q3 2024 and 18 closed out, a net change of -16 holders.
  • The largest Carisma Therapeutics buyer in Q3 2024 was Barclays, an estimated $595K added.
  • The largest Carisma Therapeutics seller in Q3 2024 was Goldman Sachs, an estimated $354K sold.

Based on aggregated 13F filings for Q3 2024.